Back to top
more

AMN Healthcare Services (AMN)

(Real Time Quote from BATS)

$40.79 USD

40.79
105,554

+1.12 (2.82%)

Updated Oct 28, 2024 11:44 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Medtronic (MDT) to Buy Affera, Expand in Electrophysiology

by Zacks Equity Research

Affera's full suite of solutions and technologies will complement Medtronic's (MDT) existing atrial and ventricular arrhythmia disease management portfolio.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from improving the adoption of the da Vince Surgical System. Higher production costs are a woe.

PacBio's (PACB) Sequel IIe Boosts Radboudumc's Sequencing Ability

by Zacks Equity Research

PacBio's (PACB) sequencing system enhances Radboudumc's SMRT sequencing capability through the addition of two new PacBio Sequel IIe systems.

BD (BDX) Product Gets FDA Nod, Patient Outcome to Get a Boost

by Zacks Equity Research

Regulatory clearance for BD's (BDX) Kiestra IdentifA system is expected to lead to better patient management via automated sample processing and MALDI target preparation.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS), owing to consistent improvement in its consumer-centric digital solutions and raised guidance.

NuVasive (NUVA) Gets FDA Nod for Attrax Putty Expanded Use

by Zacks Equity Research

NuVasive's (NUVA) Attrax Putty is the first and only synthetic biologic to receive 510(k) indications for use in interbody fusions of the thoracolumbar spine.

Thermo Fisher (TMO) Completes Buyout of PeproTech for $1.85B

by Zacks Equity Research

Thermo Fisher's (TMO) recent acquisition will boost its capabilities to serve in the high-growth cell and gene therapy market.

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

AngioDynamics (ANGO) Q2 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs, as well as in domestic and international revenues in fiscal 2022 Q2.

Illumina (ILMN)-SomaLogic Ink Deal to Advance Proteomics

by Zacks Equity Research

Illumina's (ILMN) collaboration with SomaLogic will boost the fast-growing high throughput sector of the proteomics market to aid research in biology and disease.

Hologic's (HOLX) GAI Program to Include Aptima SARS-CoV-2 Assay

by Zacks Equity Research

The addition of Aptima SARS-CoV-2 assay to Hologic's (HOLX) Global Access Initiative is likely to improve its accessibility.

AMN Healthcare Services (AMN) Stock Moves -1.68%: What You Should Know

by Zacks Equity Research

In the latest trading session, AMN Healthcare Services (AMN) closed at $118.61, marking a -1.68% move from the previous day.

STERIS (STE) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Strong segmental performances are driving the top line for STERIS (STE).

3 Reasons to Retain Integer Holdings (ITGR) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and solid foothold in the broader MedTech space.

Here's Why You Should Retain Phibro (PAHC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Phibro (PAHC), given robust performance by its nutritional specialties and vaccine product lines.

Omnicell (OMCL) to Expand EnlivenHealth Division With New Buyout

by Zacks Equity Research

Omnicell's (OMCL) $82-million buyout of MarkeTouch Media is likely to expand its Advanced Services portfolio.

AMN Healthcare Services (AMN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed the most recent trading day at $120.64, moving -0.13% from the previous trading session.

3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.

Nilanjan Banerjee headshot

Fretting Over Market Volatility? Bet on These 4 Low-Beta Stocks

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. AMN Healthcare (AMN), Vista Outdoor (VSTO), Sensus Healthcare (SRTS) and Ameresco (AMRC) are well poised to gain.

Why Should You Hold Universal Health (UHS) in Your Portfolio?

by Zacks Equity Research

Riding high on strategic measures and a solid solvency level, Universal Health (UHS) holds prospects to reap benefits for investors.

3 Reasons to Add McKesson (MCK) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about McKesson (MCK) owing to its robust Biologics business.

Quidel's (QDEL) Antigen Tests Successful in Omicron Detection

by Zacks Equity Research

The success of Quidel's (QDEL) antigen tests against Omicron is expected to lead to better access to affordable COVID-19 testing.

Trina Mukherjee headshot

Forget DaVita (DVA), Buy These 3 Lucrative Medical Care Stocks

by Trina Mukherjee

With stocks offering dialysis services, including DaVita (DVA), facing several issues, it would be prudent to invest in medical care and services stocks like DGX, AMN and CODX instead for 2022.

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

PacBio's (PACB) New Surveillance Kit Successful Against Omicron

by Zacks Equity Research

PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.